28005193|t|TREK-1 (K2P2.1) K(+) channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control
28005193|a|Atrial fibrillation (AF) is the most common cardiac arrhythmia. Concomitant heart failure (HF) poses a particular therapeutic challenge and is associated with prolonged atrial electrical refractoriness compared with non-failing hearts. We hypothesized that downregulation of atrial repolarizing TREK-1 (K2P2.1) K(+) channels contributes to electrical remodeling during AF with HF, and that TREK-1 gene transfer would provide rhythm control via normalization of atrial effective refractory periods in this AF subset. In patients with chronic AF and HF, atrial TREK-1 mRNA levels were reduced by 82% (left atrium) and 81% (right atrium) compared with sinus rhythm (SR) subjects. Human findings were recapitulated in a porcine model of atrial tachypacing-induced AF and reduced left ventricular function. TREK-1 mRNA (-66%) and protein (-61%) was suppressed in AF animals at 14-day follow-up compared with SR controls. Downregulation of repolarizing TREK-1 channels was associated with prolongation of atrial effective refractory periods versus baseline conditions, consistent with prior observations in humans with HF. In a preclinical therapeutic approach, pigs were randomized to either atrial Ad-TREK-1 gene therapy or sham treatment. Gene transfer effectively increased TREK-1 protein levels and attenuated atrial effective refractory period prolongation in the porcine AF model. Ad-TREK-1 increased the SR prevalence to 62% during follow-up in AF animals, compared to 35% in the untreated AF group. In conclusion, TREK-1 downregulation and rhythm control by Ad-TREK-1 transfer suggest mechanistic and potential therapeutic significance of TREK-1 channels in a subgroup of AF patients with HF and prolonged atrial effective refractory periods. Functional correction of ionic remodeling through TREK-1 gene therapy represents a novel paradigm to optimize and specify AF management.
28005193	0	29	TREK-1 (K2P2.1) K(+) channels	T116,T123	C0754471
28005193	34	44	suppressed	T169	C1260953
28005193	48	56	patients	T101	C0030705
28005193	62	81	atrial fibrillation	T047	C0004238
28005193	86	99	heart failure	T047	C0018801
28005193	104	111	provide	T052	C1999230
28005193	112	131	therapeutic targets	T169	C0302350
28005193	136	150	rhythm control	T080	C0243148
28005193	151	170	Atrial fibrillation	T047	C0004238
28005193	172	174	AF	T047	C0004238
28005193	195	213	cardiac arrhythmia	T033	C0003811
28005193	215	240	Concomitant heart failure	T047	C0018801
28005193	242	244	HF	T047	C0018801
28005193	265	276	therapeutic	T169	C0302350
28005193	277	286	challenge	T059	C1315011
28005193	310	319	prolonged	T079	C0439590
28005193	320	352	atrial electrical refractoriness	T040	C0034954
28005193	367	385	non-failing hearts	T023	C0018787
28005193	408	422	downregulation	T044	C0013081
28005193	426	445	atrial repolarizing	T042	C1371280
28005193	446	475	TREK-1 (K2P2.1) K(+) channels	T116,T123	C0754471
28005193	476	487	contributes	T052	C1880177
28005193	491	512	electrical remodeling	T046	C3658220
28005193	520	522	AF	T047	C0004238
28005193	528	530	HF	T047	C0018801
28005193	541	561	TREK-1 gene transfer	T063	C1517499
28005193	576	590	rhythm control	T080	C0243148
28005193	595	608	normalization	T062	C1882115
28005193	612	647	atrial effective refractory periods	T033	C0428938
28005193	656	658	AF	T047	C0004238
28005193	659	665	subset	T062	C2986480
28005193	670	678	patients	T101	C0030705
28005193	684	694	chronic AF	T047	C0694539
28005193	699	701	HF	T047	C0018801
28005193	703	716	atrial TREK-1	T116,T123	C0754471
28005193	717	721	mRNA	T114,T123	C0035696
28005193	722	728	levels	T080	C0441889
28005193	750	761	left atrium	T023	C0225860
28005193	772	784	right atrium	T023	C0225844
28005193	800	812	sinus rhythm	T033	C0232201
28005193	814	816	SR	T033	C0232201
28005193	818	826	subjects	T098	C0080105
28005193	828	833	Human	T016	C0086418
28005193	834	842	findings	T033	C0243095
28005193	867	880	porcine model	T075	C0026336
28005193	884	913	atrial tachypacing-induced AF	T047	C0004238
28005193	918	925	reduced	T080	C0392756
28005193	926	951	left ventricular function	T042	C0080310
28005193	953	959	TREK-1	T116,T123	C0754471
28005193	960	964	mRNA	T114,T123	C0035696
28005193	976	983	protein	T116,T123	C0754471
28005193	995	1005	suppressed	T169	C1260953
28005193	1009	1011	AF	T047	C0004238
28005193	1012	1019	animals	T008	C0003062
28005193	1040	1048	compared	T052	C1707455
28005193	1054	1056	SR	T033	C0232201
28005193	1067	1081	Downregulation	T044	C0013081
28005193	1085	1097	repolarizing	T042	C1371280
28005193	1098	1113	TREK-1 channels	T116,T123	C0754471
28005193	1134	1146	prolongation	T079	C0439590
28005193	1150	1185	atrial effective refractory periods	T033	C0428938
28005193	1193	1201	baseline	T081	C1442488
28005193	1214	1229	consistent with	T078	C0332290
28005193	1230	1235	prior	T079	C0332152
28005193	1236	1248	observations	T062	C0302523
28005193	1252	1258	humans	T016	C0086418
28005193	1264	1266	HF	T047	C0018801
28005193	1273	1284	preclinical	T080	C1709630
28005193	1285	1305	therapeutic approach	T169	C0302350
28005193	1307	1311	pigs	T015	C0039005
28005193	1317	1327	randomized	T062	C0034656
28005193	1338	1367	atrial Ad-TREK-1 gene therapy	T061	C0017296
28005193	1371	1385	sham treatment	T061	C0032042
28005193	1387	1400	Gene transfer	T063	C1517499
28005193	1401	1412	effectively	T080	C1280519
28005193	1413	1422	increased	T081	C0205217
28005193	1423	1437	TREK-1 protein	T116,T123	C0754471
28005193	1438	1444	levels	T080	C0441889
28005193	1449	1459	attenuated	T052	C0599946
28005193	1460	1494	atrial effective refractory period	T033	C0428938
28005193	1495	1507	prolongation	T079	C0439590
28005193	1515	1531	porcine AF model	T075	C0026336
28005193	1533	1542	Ad-TREK-1	T116,T123	C0754471
28005193	1557	1559	SR	T033	C0232201
28005193	1560	1570	prevalence	T081	C0033105
28005193	1598	1600	AF	T047	C0004238
28005193	1601	1608	animals	T008	C0003062
28005193	1610	1618	compared	T052	C1707455
28005193	1643	1645	AF	T047	C0004238
28005193	1656	1666	conclusion	T078	C1707478
28005193	1668	1674	TREK-1	T116,T123	C0754471
28005193	1675	1689	downregulation	T044	C0013081
28005193	1694	1708	rhythm control	T080	C0243148
28005193	1712	1730	Ad-TREK-1 transfer	T063	C1517499
28005193	1731	1738	suggest	T078	C1705535
28005193	1739	1776	mechanistic and potential therapeutic	T061	C0087111
28005193	1777	1789	significance	T078	C0750502
28005193	1793	1808	TREK-1 channels	T116,T123	C0754471
28005193	1814	1822	subgroup	T185	C1515021
28005193	1826	1828	AF	T047	C0004238
28005193	1829	1837	patients	T101	C0030705
28005193	1843	1845	HF	T047	C0018801
28005193	1850	1859	prolonged	T079	C0439590
28005193	1860	1895	atrial effective refractory periods	T033	C0428938
28005193	1897	1918	Functional correction	T169	C0205245
28005193	1947	1966	TREK-1 gene therapy	T061	C0017296
28005193	1980	1985	novel	T080	C0205314
28005193	1986	1994	paradigm	T062	C0681797
28005193	2019	2021	AF	T047	C0004238